Factors affecting local recurrence and distant metastases of invasive breast cancer after breast-conserving surgery in Chiang Mai University Hospital

Figures & data

Figure 1 Flowchart shows data collection of breast-conserving surgery patients and divided subgroups.

Abbreviations: BCS, breast-conserving surgery; LVI, lymphovascular invasion; LN, lymph-node; SLN, sentinel LN; ALND, axillary LN dissection; T, tumor; N, node involvement; ER, estrogen receptor; PR, progesterone receptor; HER2: human epidermal growth factor receptor 2.

Table 1 Patient characteristics

	Recurrence (n)	Nonrecurrence (n)	P-value
Patients (n=185)	19 (10.27%)	166 (89.73%)
Average age, years (range)	41.11 (36.98–45.23)	47.48 (45.94–49.02)	0.0085
Menopausal status			0.047
Premenopausal	19 (10.27%)	137 (74.1%)
Menopausal	0	29 (15.68%)

Abbreviation: SD, standard deviation.

Table 2 Histologic type of invasive breast cancer

	Recurrence (n)	Nonrecurrence (n)	P-value
Histologic type			0.323
Ductal carcinoma	17 (9.19%)	149 (80.54%)
Lobular carcinoma	0	4 (2.16%)
Papillary carcinoma	1 (0.54%)	5 (2.70%)
Medullary carcinoma	0	3 (1.62%)
Mucinous carcinoma	0	4 (2.16%)
Tubular carcinoma	0	1 (0.54%)
Neuroendocrine	1 (0.54%)	0

Table 3 Clinicopathologic characteristics

	Recurrence (n)	Nonrecurrence (n)	P-value
Clinical T			0.219
T1	18 (9.73%)	162 (87.57%)
T2	0	3 (1.62%)
T3	1 (0.54%)	1 (0.54%)
Clinical N			0.227
N0	14 (7.57%)	139 (73.13%)
N1	4 (2.16%)	23 (12.43%)
N2	0	3 (1.62%)
N3	1 (0.54)	1 (0.54%)
Histologic grade			0.611
1	0	8 (4.32%)
2	8 (4.32%)	80 (43.24%)
3	9 (4.86%)	63 (34.05%)
Nuclear grade			0.458
1	0	12 (6.49%)
2	8 (4.32%)	74 (40%)
3	10 (5.41%)	66 (35.68%)
ER status			0.001
0	10 (5.62%)	53 (29.78%)
1+	3 (1.69%)	11 (6.18%)
2+	4 (2.25%)	11 (6.18%)
3+	2 (1.12%)	84 (47.19%)
PR status			0.003
0	11 (6.18%)	68 (38.20%)
1+	2 (1.12%)	18 (10.11%)
2+	5 (2.81%)	12 (6.74%)
3+	1 (0.56%)	61 (34.27%)
HER2 status			0.224
Negative	10 (5.41%)	89 (48.11%)
Equivocal (2+)	3 (1.62%)	35 (18.92%)
3+	6 (3.24%)	32 (17.3%)
Triple-negative			0.337
No	126 (73.68%)	13 (7.60%)
Yes	27 (15.79%)	5 (2.92%)
LVI			0.583
Negative	93 (54.07%)	11 (6.39%)
Positive	61 (35.47%)	7 (4.07%)

Abbreviations: LVI, lymphovascular invasion; T, tumor; N, node involvement; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.

Table 4 Lymph-node operation and margin status

	Recurrence (n)	Nonrecurrence (n)	P-value
Lymph-node operation			0.107
SLN	13 (7.10%)	83 (45.36%)
ALND	4 (2.19%)	76 (41.53%)
SLN-positive, then ALND	1 (0.55%)	6 (3.28%)
Number of positive LNs			0.066
LN-positive 0–2	13 (7.10%)	146 (79.78%)
LN-positive ≥3	5 (2.73%)	19 (10.38%)
Margin status			0.63
Negative	17 (9.34%)	152 (83.52%)
Positive	2 (1.1%)	11 (6.04%)

Abbreviations: LN, lymph-node; SLN, sentinel LN; ALND, axillary LN dissection.

Table 5 Type of chemotherapy and antihormonal treatment

	Recurrence (n)	Nonrecurrence (n)	P-value
Type of chemotherapy			0.646
Neoadjuvant	2 (1.09%)	13 (7.10%)
Adjuvant	16 (8.74%)	152 (83.06%)
Trastuzumab			0.252
Yes	2 (1.10%)	9 (4.97%)
No	14 (7.73%)	156 (86.19%)
Hormonal treatment			0.011
None	12 (6.59%)	56 (30.77%)
Tamoxifen	5 (2.75%)	84 (46.15%)
Aromatase inhibitor	0	22 (12.09%)
Switching	1 (0.55%)	2 (1.10%)

Figure 2 Kaplan–Meier survival estimates.